Iridex Reports First Quarter 2023 Financial Results
12 5월 2023 - 5:05AM
Iridex Corporation (Nasdaq: IRIX), a provider of innovative
ophthalmic laser-based medical products for the treatment of
glaucoma and retinal diseases, today reported financial results for
the first quarter ended April 1, 2023.
First Quarter 2023 Highlights
- Generated total revenue of $13.7 million, an increase of 2%
year-over-year
- Cyclo G6® product family revenue of $3.7 million increased 4%
year-over-year
- 61 Cyclo G6 Glaucoma Laser Systems sold, compared to 56 in the
prior year period
- Cyclo G6 probe revenue increased 6% year-over-year on decreased
unit sales of 13,800 probes
- Retina product revenue of $7.2 million was essentially flat
year-over-year
- Received FDA clearance in February for the new single-spot
laser platform for the Iridex 532 and Iridex 577 systems
- Cash and cash equivalents totaled approximately $11.0 million
as of April 1, 2023
“In addition to receiving FDA clearance in February for our
second key laser platform, we were pleased to achieve 19%
year-over-year growth in U.S. G6 probe revenue,” said David Bruce,
President and CEO. “Although we experienced a modest decline in
year-over-year glaucoma probe unit sales resulting from continued
international distributor order volatility after a record fourth
quarter, we saw strength in international purchases of glaucoma
systems. We remain confident in our activities to drive adoption
and utilization of our Cyclo G6 glaucoma treatment platform. By
leveraging our Sweep Management software and increasing awareness
of effective dosing recommendations, we expect clinicians to
experience strong clinical outcomes and consistency, leading to
increased utilization throughout the year.”
First Quarter 2023 Financial ResultsRevenue for
the three months ended April 1, 2023 was $13.7 million compared to
$13.4 million during the same period of the prior year. Total
product revenue from the Cyclo G6 glaucoma product group was $3.7
million, an increase of 4% compared to the first quarter of 2022,
driven by strong probe ASP growth in the U.S. Retina product
revenue in the first quarter was $7.2 million compared to $7.3
million in the prior year, a decrease of 1%. Other revenue, which
includes royalties, services, and other legacy products, increased
11% to $2.8 million in the first quarter of 2023 compared to the
prior year, primarily driven by higher revenue from Other legacy
products.
Gross profit for the first quarter of 2023 remained essentially
unchanged at $5.9 million or a 43.3% gross margin, compared to $6.0
million, or a 44.6% gross margin, in the same period of the prior
year. The lower gross margin was the result of higher production
overhead.
Operating expenses for the first quarter of 2023 were flat at
$8.3 million for both the first quarter of 2023 and in the same
period of the prior year.
Net loss for the first quarter of 2023 was $2.1 million, or
$0.13 per share, compared to a net loss of $2.4 million, or $0.15
per share, in the same period of the prior year.
Cash and cash equivalents totaled $11.0 million as of April 1,
2023. Cash use of $2.9 million in the first quarter included items
unique to the first quarter and cash usage is expected to decrease
significantly in the remaining quarters of 2023 as inventory levels
decrease.
Guidance for Full Year 2023Iridex reiterated
its financial outlook for 2023, expecting Cyclo G6 probe sales of
65,000 to 67,000 representing approximately 9% to 12% growth over
2022 and to expand the Cyclo G6 systems installed base by 225 to
250 systems. Total revenue for the full year is expected to be $57
million to $59 million. 2023 total revenue guidance represents
growth of approximately 3% to 6% after adjusting for an approximate
$1.5 million reduction of Other Revenue royalty income resulting
from the expiration of licensed patents.
Webcast and Conference Call InformationIridex’s
management team will host a conference call today beginning at 2:00
p.m. PT / 5:00 p.m. ET. Investors interested in listening to the
conference call may do so by accessing the live and recorded
webcast on the “Event Calendar” page of the “Investors” section of
the Company’s website at www.iridex.com.
About IridexIridex Corporation is a
worldwide leader in developing, manufacturing, and marketing
innovative and versatile laser-based medical systems, delivery
devices and consumable instrumentation for the ophthalmology
market. The Company’s proprietary MicroPulse® technology
delivers a differentiated treatment that provides safe, effective,
and proven treatment for targeted sight-threatening eye conditions.
Iridex’s current product line is used for the treatment of glaucoma
and diabetic macular edema (DME) and other retinal
diseases. Iridex products are sold in the United
States through a direct sales force and internationally
primarily through a network of independent distributors into more
than 100 countries. For further information, visit
the Iridex website at www.iridex.com.
Safe Harbor StatementThis announcement contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Act of 1934, as amended, including those statements
concerning clinical and commercial momentum, market adoption and
expansion, demand for and utilization of the Company's products,
financial guidance and results and expected sales volumes. These
statements are not guarantees of future performance and actual
results may differ materially from those described in these
forward-looking statements as a result of a number of factors.
Please see a detailed description of these and other risks
contained in our Annual Report on Form 10-K filed with the
Securities and Exchange Commission for the fiscal year ended
December 31, 2022. Forward-looking statements contained in this
announcement are made as of this date and will not be updated.
Investor Relations ContactPhilip
TaylorGilmartin Groupinvestors@iridex.com
IRIDEX
CorporationCondensed Consolidated Statements of
Operations(In thousands, except per share
data)(unaudited)
|
|
Three Months Ended |
|
|
|
April 1, |
|
|
April 2, |
|
|
|
2023 |
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
$ |
13,706 |
|
|
$ |
13,387 |
|
Cost of revenues |
|
|
7,768 |
|
|
|
7,410 |
|
Gross profit |
|
|
5,938 |
|
|
|
5,977 |
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Research and development |
|
|
1,749 |
|
|
|
2,116 |
|
Sales and marketing |
|
|
4,283 |
|
|
|
4,300 |
|
General and administrative |
|
|
2,250 |
|
|
|
1,838 |
|
Total operating expenses |
|
|
8,282 |
|
|
|
8,254 |
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(2,344 |
) |
|
|
(2,277 |
) |
Other income (expense),
net |
|
|
266 |
|
|
|
(94 |
) |
Loss from operations before
provision for income taxes |
|
|
(2,078 |
) |
|
|
(2,371 |
) |
Provision for income
taxes |
|
|
12 |
|
|
|
20 |
|
Net loss |
|
$ |
(2,090 |
) |
|
$ |
(2,391 |
) |
|
|
|
|
|
|
|
|
|
Net loss per share: |
|
|
|
|
|
|
|
|
Basic |
|
$ |
(0.13 |
) |
|
$ |
(0.15 |
) |
Diluted |
|
$ |
(0.13 |
) |
|
$ |
(0.15 |
) |
|
|
|
|
|
|
|
|
|
Weighted average shares used
in computing net loss per share |
|
|
|
|
|
|
|
|
Basic |
|
|
16,001 |
|
|
|
15,881 |
|
Diluted |
|
|
16,001 |
|
|
|
15,881 |
|
IRIDEX
CorporationCondensed Consolidated Balance
Sheets(In thousands and unaudited)
|
|
April 1, |
|
|
December 31, |
|
|
|
2023 |
|
|
2022 |
|
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
11,048 |
|
|
$ |
13,922 |
|
Accounts receivable, net |
|
|
10,759 |
|
|
|
9,768 |
|
Inventories |
|
|
11,241 |
|
|
|
10,608 |
|
Prepaid expenses and other current assets |
|
|
1,650 |
|
|
|
1,468 |
|
Total current assets |
|
|
34,698 |
|
|
|
35,766 |
|
Property and equipment,
net |
|
|
449 |
|
|
|
462 |
|
Intangible assets, net |
|
|
1,894 |
|
|
|
1,977 |
|
Goodwill |
|
|
965 |
|
|
|
965 |
|
Operating lease right-of-use
assets, net |
|
|
1,423 |
|
|
|
1,665 |
|
Other long-term assets |
|
|
1,551 |
|
|
|
1,455 |
|
Total assets |
|
$ |
40,980 |
|
|
$ |
42,290 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
3,669 |
|
|
$ |
3,873 |
|
Accrued compensation |
|
|
2,813 |
|
|
|
2,448 |
|
Accrued expenses |
|
|
2,132 |
|
|
|
1,548 |
|
Other current liabilities |
|
|
882 |
|
|
|
968 |
|
Accrued warranty |
|
|
196 |
|
|
|
168 |
|
Deferred revenue |
|
|
2,424 |
|
|
|
2,411 |
|
Operating lease liabilities |
|
|
1,046 |
|
|
|
1,037 |
|
Total current liabilities |
|
|
13,162 |
|
|
|
12,453 |
|
|
|
|
|
|
|
|
|
|
Long-term liabilities: |
|
|
|
|
|
|
|
|
Accrued warranty |
|
|
124 |
|
|
|
106 |
|
Deferred revenue |
|
|
11,312 |
|
|
|
11,742 |
|
Operating lease liabilities |
|
|
472 |
|
|
|
732 |
|
Other long-term liabilities |
|
|
26 |
|
|
|
26 |
|
Total liabilities |
|
|
25,096 |
|
|
|
25,059 |
|
|
|
|
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
|
|
|
Common stock |
|
|
169 |
|
|
|
169 |
|
Additional paid-in capital |
|
|
87,312 |
|
|
|
86,802 |
|
Accumulated other comprehensive loss |
|
|
(35 |
) |
|
|
(24 |
) |
Accumulated deficit |
|
|
(71,562 |
) |
|
|
(69,716 |
) |
Total stockholders' equity |
|
|
15,884 |
|
|
|
17,231 |
|
Total liabilities and stockholders' equity |
|
$ |
40,980 |
|
|
$ |
42,290 |
|
IRIDEX (NASDAQ:IRIX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
IRIDEX (NASDAQ:IRIX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024